<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376608</url>
  </required_header>
  <id_info>
    <org_study_id>CTN00714101</org_study_id>
    <nct_id>NCT02376608</nct_id>
  </id_info>
  <brief_title>Bioavailability of Omega-3 Food Supplement in Healthy Subjects</brief_title>
  <official_title>Pronovum - An Open-label, Randomized, Single-dose Study to Evaluate the Bioavailability of Omega-3 Food Supplements in Healthy Male and Female Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pronova BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pronova BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the relative bioavailability of Pronovum PRF-037 and Pronovum PRF-041
      with PronovaPure 150:150 EE EU and Eskimo-3 (500 mg omega-3 acid triglyceride containing 80
      mg EPA and 50 mg DHA per gram oil) in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve of omega-3 food supplements under light fed conditions in healthy subjects.</measure>
    <time_frame>Pharmacikinetics up to 36 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma concentration of omega-3 food supplements under light fed conditions in healthy subjects.</measure>
    <time_frame>Pharmacikinetics up to 36 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability.</measure>
    <time_frame>During entire study period, an expected average of 7 weeks from screening to last visit.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Biological Availability</condition>
  <arm_group>
    <arm_group_label>Pronova Pure 150:500 EE EU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 × PronovaPure 150:500 EE EU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pronovum PRF-037</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 × Pronovum PRF-037</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pronovum PRF-041</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 × Pronovum PRF-041</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eskimo-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 × Eskimo-3</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pronova Pure 150:500 EE EU</intervention_name>
    <description>Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period</description>
    <arm_group_label>Pronova Pure 150:500 EE EU</arm_group_label>
    <arm_group_label>Pronovum PRF-037</arm_group_label>
    <arm_group_label>Pronovum PRF-041</arm_group_label>
    <arm_group_label>Eskimo-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pronovum PRF-037</intervention_name>
    <description>Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period</description>
    <arm_group_label>Pronova Pure 150:500 EE EU</arm_group_label>
    <arm_group_label>Pronovum PRF-037</arm_group_label>
    <arm_group_label>Pronovum PRF-041</arm_group_label>
    <arm_group_label>Eskimo-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pronovum PRF-041</intervention_name>
    <description>Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period</description>
    <arm_group_label>Pronova Pure 150:500 EE EU</arm_group_label>
    <arm_group_label>Pronovum PRF-037</arm_group_label>
    <arm_group_label>Pronovum PRF-041</arm_group_label>
    <arm_group_label>Eskimo-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Eskimo-3</intervention_name>
    <description>Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period</description>
    <arm_group_label>Pronova Pure 150:500 EE EU</arm_group_label>
    <arm_group_label>Pronovum PRF-037</arm_group_label>
    <arm_group_label>Pronovum PRF-041</arm_group_label>
    <arm_group_label>Eskimo-3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males or females

          -  any ethnic origin

          -  BMI 18.5 - 30.0 kg/m2

          -  generally in good health

          -  signed informed consent

        Exclusion Criteria:

          -  males or females not willing to use appropriate contraception

          -  prescribed systemic or topical medication within 14 days and slow release medication
             considered to be active within 14 days.

          -  omega-3 fatty acids or fish oil within 2 weeks of dosing.

          -  any non-prescribed systemic or topical medication including herbal remedies and
             vitamin/mineral supplements within 7 days

          -  any medication incl. St.John's Worth known to chronically alter drug
             absorption/elimination within 30 days

          -  Subjects still present in clinical study or in the past 3 months

          -  recent blood donation

          -  drug allergy or significant allergic disease

          -  allergic or hypersensitivity to omega-3 acids, fish, soya, oleic acid, sesame oil or
             other constituents in pharma preparation

          -  high consumption of alcohol

          -  high consumption of tobacco

          -  hepatitis or HIV

          -  vegetarians

          -  earlier participated in or withdrawn from the study

          -  not willing to follow dietary restrictions

          -  frequent occurence of migraine attacks

          -  subjects that should not participate according to investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Strong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit (CRU) Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical research Unit (CRU) Ltd,Springfield House, Hyde street</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>February 25, 2015</last_update_submitted>
  <last_update_submitted_qc>February 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

